DTC
GPCR icon

Deep Track Capital’s Structure Therapeutics GPCR Stock Holding History

Deep Track Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206M Buy
4,279,848
+168,066
+4% +$11.5M 3.37% 6
2025
Q4 		$286M Sell
4,111,782
-104,029
-2% -$4.25M 5.1% 4
2025
Q3 		$118M Sell
4,215,811
-918,106
-18% -$18.3M 3.29% 11
2025
Q2 		$106M Buy
5,133,917
+1,033,917
+25% +$22.7M 3.41% 11
2025
Q1 		$71M Buy
4,100,000
+1,300,000
+46% +$31.8M 2.3% 14
2024
Q4 		$75.9M Buy
2,800,000
+1,579,492
+129% +$56M 2.83% 11
2024
Q3 		$53.6M Buy
1,220,508
+270,508
+28% +$10.5M 1.7% 22
2024
Q2 		$37.3M Buy
950,000
+909,863
+2,267% +$37.4M 1.11% 34
2024
Q1 		$1.72M Sell
40,137
-259,863
-87% -$11M 0.05% 66
2023
Q4 		$12.2M Sell
300,000
-1,615,000
-84% -$92.6M 0.41% 49
2023
Q3 		$96.6M Sell
1,915,000
-731,782
-28% -$23.6M 3.73% 9
2023
Q2 		$110M Hold
2,646,782
– – 5.09% 5
2023
Q1 		$63M Buy
+2,646,782
New +$62.2M 2.59% 14

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Deep Track Capital's GPCR Position: Q1 2026 in Review

Deep Track Capital increased its Structure Therapeutics (GPCR) stake by 4.1% in Q1 2026, buying an estimated $11.5M and bringing the position to 4,279,848 shares worth $206M. The position accounts for 3.37% of the portfolio, ranked #6.

Deep Track Capital first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $286M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Deep Track Capital held 4,279,848 shares of Structure Therapeutics worth $206M as of Q1 2026.
  • Deep Track Capital bought 168,066 Structure Therapeutics shares in Q1 2026, an estimated $11.5M.
  • Structure Therapeutics made up 3.37% of Deep Track Capital's portfolio in Q1 2026, its #6 holding.
  • Deep Track Capital first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Deep Track Capital's Structure Therapeutics position peaked at $286M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.